(Q33692770)

28 July 2017

Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety (English)

1 reference

28 July 2017

1 reference

Nahid A Qushmaq

1

1 reference

PubMed ID

24944829

28 July 2017

Samar A Al-Emadi

series ordinal

2

1 reference

28 July 2017

17 April 2014

1 reference

28 July 2017

1 reference

28 July 2017

2014

1 reference

28 July 2017

348726

1 reference

Creative Commons Attribution 3.0 Unported

28 July 2017

start time

17 April 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

B-cell directed therapies in antiphospholipid antibody syndrome--new directions based on murine and human data

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Towards evidence-based treatment of thrombotic antiphospholipid syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

New approaches for managing antiphospholipid syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Evidence-based management of thrombosis in the antiphospholipid antibody syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Prophylaxis of the antiphospholipid syndrome: a consensus report

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Antiphospholipid antibodies and thrombosis: strength of association

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Pathogenic mechanisms mediating antiphospholipid syndrome

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Clinical consequences of antiphospholipid antibodies: an historic cohort study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

14 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Recurrent miscarriage and long-term thrombosis risk: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Rituximab treatment for resistant antiphospholipid syndrome.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4040209

The blossoming of evidence-based clinical rheumatology: The Arthritis Research Campaign's Clinical Trials Collaboration in association with the MRC Clinical Trials Unit, BSR and BOA

30 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F348726

Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study

21 January 2018

1 reference

12 December 2020

Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry

1 reference

12 December 2020

The antiphospholipid syndrome

1 reference

12 December 2020

The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS

1 reference

12 December 2020

Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus

1 reference

12 December 2020

High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus

1 reference

12 December 2020

Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients

1 reference

12 December 2020

Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus

1 reference

12 December 2020

Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus

1 reference

12 December 2020

Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus

1 reference

12 December 2020

1 reference

12 December 2020

Antiphospholipid antibodies in patients with coronary artery disease: new cardiac risk factors?

1 reference

12 December 2020

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

12 December 2020

Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders

1 reference

12 December 2020

Primary antiphospholipid syndrome: functional outcome after 10 years

1 reference

12 December 2020

Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease

1 reference

12 December 2020

Identifiers

DOI

10.1155/2014/348726

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

PubMed ID

24944829